Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
April 2016, Vol 7, No 3
April 2016, Vol 7, No 3
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
By
Lisa A. Raedler, PhD, RPh
Drug Updates
April 2016, Vol 7, No 3
On November 20, 2015, the US Food and Drug Administration (FDA) approved ixazomib (Ninlaro; Takeda Oncology) capsules in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who received at least 1 previous therapy.
Read Article
Data Drive Quality Improvement in an Oncology Patient-Centered Medical Home
By
Meg Barbor, MPH
Quality Care
,
Policies & Guidelines
April 2016, Vol 7, No 3
Read Article
Tamoxifen or Anastrozole for DCIS? Age and Symptoms Matter
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
April 2016, Vol 7, No 3
Anastrozole and tamoxifen are similarly effective in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ (DCIS). The choice should depend on patient preferences, side-effect profiles, age, and other patient factors, according to 2 studies presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Survival Benefit for T-DM1 Confirmed in Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
April 2016, Vol 7, No 3
The antibody-drug conjugate trastuzumab emtansine (T-DM1) improved overall survival (OS) compared with physician’s choice of therapy in patients with pretreated HER2-positive metastatic breast cancer, according to the final results of the phase 3 TH3RESA trial, which were presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Adjuvant Therapy at High-Volume Centers Improves Pancreatic Cancer Survival
By
Charles Bankhead
GI Cancers
April 2016, Vol 7, No 3
The advantages of treatment at a high-volume center extended to adjuvant therapy in patients with resected pancreatic cancer, according to a study reported by Margaret T. Mandelson, PhD, MPH, Floyd and Dolores Jones Cancer Institute, Virginia Mason Medical Center, Seattle, WA, at the 2016 Gastrointestinal Cancers Symposium.
Read Article
Reirradiation of Pelvic Area Safe, Improves Quality of Life
By
Phoebe Starr
Genitourinary Cancers
April 2016, Vol 7, No 3
Experience at a high-volume cancer center suggests that nonstereotactic body radiotherapy external beam reirradiation of the pelvis for cancer recurrence or for a second genitourinary malignancy is safe in patients with advanced cancer, and can achieve excellent and durable palliation of symptoms without severe radiation-induced morbidity.
Read Article
Integrating Survivorship Care in Oncology: A Conversation with Patricia Ganz, MD
By
Patricia Ganz, MD
Survivorship
,
Policies & Guidelines
April 2016, Vol 7, No 3
At the 2016 Cancer Survivorship Symposium, Dr Ganz spoke with
Value-Based Cancer Care
(
VBCC
) about the importance of cancer rehabilitation, the politics of surveillance, and the greatest unmet needs facing survivors.
Read Article
Checkpoint Inhibitors Active in Gastric and Esophageal Cancers
By
Charles Bankhead
GI Cancers
April 2016, Vol 7, No 3
Immune checkpoint inhibitors demonstrated varying degrees of activity in advanced gastric and esophageal cancers, according to preliminary clinical studies reported at the 2016 Gastrointestinal Cancers Symposium.
Read Article
Impact of Financial Toxicity on Health-Related Quality of Life
By
Chase Doyle
Value in Oncology
April 2016, Vol 7, No 3
Researchers in Chicago have developed a financial toxicity grading system based on clinically meaningful changes in health-related quality of life. According to lead investigator Jonas A. de Souza, MD, Assistant Professor of Medicine, University of Chicago, at the 2016 Cancer Survivorship Symposium, the tool has been validated in 2 separate cohorts of patients with cancer, with plans for a larger, prospective study underway.
Read Article
Another Study Shows Benefit of Pediatric Regimen in Young Adults with Acute Lymphoblastic Leukemia
By
Phoebe Starr
Hematologic Malignancies
April 2016, Vol 7, No 3
A pediatric regimen achieves superior outcomes compared with adult regimens in adolescents and young adults with acute lymphoblastic leukemia (ALL). Several studies have already shown this outcome, and a multicenter phase 2 study presented at ASH 2015 adds further confirmatory evidence in support of this approach.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma